Healthcare big data and AI firm signs China deal with AstraZeneca
Nine Health Global, a Leeds-based healthcare big data and artificial intelligence company, has signed an agreement to establish a subsidiary in China.
It will be based at Wuxi International Life Science Innovation Campus (I-Campus) in Wuxi, Jiangsu province.
I-Campus is an innovation incubation platform which opened in September 2019 in Wuxi, a major centre in China for the Internet of Things and big data.
I-Campus is a joint initiative by AstraZeneca, the global pharmaceutical company, and Wuxi municipal government.
It aims to create a life-science ecosystem on a global scale, covering research & development, incubation and commercialisation for innovative Chinese and international companies in the areas of pharmaceuticals, diagnostics, devices and digitalization.
Nine Health is a big data and AI company which designs and implements systems for healthcare providers, medical device manufacturers and others.
Nine Health Global’s sister company, Nine Health Community Interest Company, was a key participant in Virtual Physiological Human – a major European Union funded in-silico medicine programme.
Nine Health has been active in China since 2014. Its achievements so far include jointly developing Diagbot, an evidence-based AI clinical decision support system which supports doctors in community clinics in China to make accurate diagnoses, together with a Chinese partner.
Nine Health is also active in Chengdu, Sichuan province, where it is leading the population health component of a major project to create a third-generation primary healthcare service.
Elaine Taylor-Whilde, founder and CEO of the Nine Health companies, said: “We have had valuable support from the UK’s Department of International Trade, Healthcare UK and the China-Britain Business Council in identifying opportunities and guiding our work in China, and from NatWest Bank’s Entrepreneur Accelerator in Leeds.
“It’s important for the UK to understand the scale of the incentives available to small and medium-sized companies setting up in China, and the size and nature of the opportunities here.”
